Tryptamine Therapeutics Limited
TYPTF
$0.015
$0.000.00%
| 12/31/2024 | 09/30/2024 | 02/29/2024 | 11/30/2023 | 08/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 580.30K | 596.70K | 493.10K | -- | -- |
| Gross Profit | -580.30K | -596.70K | -493.10K | -- | -- |
| SG&A Expenses | 706.00K | 726.00K | 492.90K | 505.90K | 494.40K |
| Depreciation & Amortization | 6.60K | 6.80K | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.29M | 1.33M | 790.60K | 696.50K | 803.60K |
| Operating Income | -1.29M | -1.33M | -790.60K | -696.50K | -803.60K |
| Income Before Tax | -1.31M | -1.35M | -914.30K | -850.10K | -1.17M |
| Income Tax Expenses | -- | -- | -- | -- | 96.10K |
| Earnings from Continuing Operations | -1.31M | -1.35M | -914.30K | -850.10K | -1.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.31M | -1.35M | -914.30K | -850.10K | -1.27M |
| EBIT | -1.29M | -1.33M | -790.60K | -696.50K | -803.60K |
| EBITDA | -1.29M | -1.32M | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.14B | 1.14B | 96.42M | 93.38M | 93.38M |
| Average Diluted Shares Outstanding | 1.14B | 1.14B | 96.42M | 93.38M | 93.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
